DVAX Research and Charts

DVAX - Dynavax Technologies Corp (Healthcare: Drug Manufacturers - Specialty & Generic)

Projected Earnings Date: 2024-08-05 (Delayed quote data 2025-06-30)

Last 9.92	Change ⇑ +0.01 (+0.10%)	Volume 1,452,535
	Open 9.89	High 10.13	Low 9.81

8EMA (Daily) 9.95	40EMA (Daily) 10.28	50EMA (Daily) 10.45	STO (Daily) 25.049	MACD Hist (Daily) 0.016
8EMA (Weekly) 10.153	40EMA (Weekly) 11.45	50EMA (Weekly) 11.59	STO (Weekly) 17.022	MACD Hist (Weekly) -0.214


Company Profile
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its HEPLISAV-B product.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.